Oncofetal Protein IMP3, a Molecular Marker for the Malignant Progression of Ovarian Serous Neoplasm
Steven Goodman, Xiaofang Yang, Di Lu. Umass Memorial Medical Center, Worcester, MA
Background: The aim of this study was to establish the expression pattern and diagnostic value of IMP3 in benign serous cystadenomas, borderline cystadenomas, and serous carcinomas of the ovary.
Design: A total of 108 cases (oopherectomy specimens) (serous cystadenoma, n=15; borderline cystadenoma; n=17, serous carcinoma; n=74) obtained from the surgical pathology files of the Umass Medical Center were examined by immunohistochemistry for IMP3 expression. The epithelial/tumor cell staining with IMP3 was recorded by percentage for each lesion. Positive staining in greater than 15% of tumor cells is a positive result.
Results: IMP3 demonstrated dark brown cytoplasmic staining(See Figure 1). IMP3 expression averaged 5% in cystadenomas (range 0-25%, median 5%), 12% in borderline tumors (range 0-75%, median 5%), and 64% in serous carcinomas (range 5-100%, median 80%)(See Figure 2).
Conclusions: IMP3 is highly expressed in malignant serous tumors of the ovary but not, or rarely in benign or borderline tumors. The data suggest that IMP3 may play an important role in malignant transformation in serous ovarian cancer. Negative staining for IMP3 can increase the level of confidence in establishing a definitive diagnosis of a benign or borderline tumor, and positive IMP3 staining for a malignancy.
Category: Gynecologic & Obstetrics
Tuesday, March 20, 2012 9:30 AM
Poster Session III # 197, Tuesday Morning